Skip to main content
SpringerLink
Log in

Applications of Botulinum Toxin in the Urinary Tract

  • Chapter
  • First Online:
Botulinum Toxin Treatment in Clinical Medicine

  • 986 Accesses

Abstract

Robust evidence exists supporting the effectiveness of Botulinum toxin A (BoNTA) in the treatment of lower urinary tract disorders including neurogenic detrusor overactivity and non-neurogenic overactive bladder. Following several randomized controlled trials with promising outcomes, the US Food and Drug Administration approved application of BoNTA for treatment of urge urinary incontinence due to neurogenic detrusor overactivity in 2011 and for overactive bladder in 2013. Following regulatory approval, use of BoNTA has gained popularity among urologists. This chapter outlines applications of BoNTA in the management of lower urinary tract disorders and presents most recent data regarding efficacy, side effects, and cost-effectiveness of BoNTA in urologic applications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Benoit RM, et al. Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. Nature. 2014;505(7481):108–11.

    Article  PubMed  Google Scholar 

  2. Dong M, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006;312(5773):592–6.

    Article  CAS  PubMed  Google Scholar 

  3. Coelho A, et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol. 2010;57(5):884–90.

    Article  CAS  PubMed  Google Scholar 

  4. Hawthorn MH, et al. Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol. 2000;129(3):416–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor—which is the main mechanism of action? Eur Urol. 2003;43(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  6. Hanna-Mitchell AT, et al. Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Neurourol Urodyn. 2015;34(1):79–84.

    Article  CAS  PubMed  Google Scholar 

  7. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49(4):644–50.

    Article  CAS  PubMed  Google Scholar 

  8. Dykstra DD, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22.

    Article  CAS  PubMed  Google Scholar 

  9. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(9):665.

    Article  CAS  PubMed  Google Scholar 

  10. Ginsberg D, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9.

    Article  CAS  PubMed  Google Scholar 

  11. Cruz F, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50.

    Article  CAS  PubMed  Google Scholar 

  12. Nitti VW, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93.

    Article  CAS  PubMed  Google Scholar 

  13. Chapple C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.

    Article  CAS  PubMed  Google Scholar 

  14. Gormley EA, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80.

    Article  PubMed  Google Scholar 

  15. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Schurch B, et al. Botulinum-a toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.

    Article  CAS  PubMed  Google Scholar 

  17. Schurch B, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200.

    Article  CAS  PubMed  Google Scholar 

  18. Ehren I, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41(4):335–40.

    Article  CAS  PubMed  Google Scholar 

  19. Giannantoni A, et al. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55(3):705–11.

    Article  CAS  PubMed  Google Scholar 

  20. Kennelly M, et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn. 2015;36(2):368–75.

    Article  PubMed  Google Scholar 

  21. Schulte-Baukloh H, et al. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology. 2002;59(3):325–7. discussion 327–8

    Article  CAS  PubMed  Google Scholar 

  22. Game X, et al. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol. 2009;5(3):156–64.

    Article  PubMed  Google Scholar 

  23. Figueroa V, et al. Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: effect of dose adjustment, multiple injections, and avoidance of reconstructive procedures. J Pediatr Urol. 2014;10(2):368–73.

    Article  CAS  PubMed  Google Scholar 

  24. Stewart WF, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.

    CAS  PubMed  Google Scholar 

  25. Dykstra D, Enriquez A, Valley M. Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(6):424–6.

    Article  PubMed  Google Scholar 

  26. Dmochowski R, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22.

    Article  CAS  PubMed  Google Scholar 

  27. Denys P, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61(3):520–9.

    Article  CAS  PubMed  Google Scholar 

  28. Sievert KD, et al. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract. 2014;68(10):1246–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Visco AG, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Andersen JT, Bradley WE. The syndrome of detrusor-sphincter dyssynergia. J Urol. 1976;116(4):493–5.

    Article  CAS  PubMed  Google Scholar 

  31. Schurch B, et al. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996;155(3):1023–9.

    Article  CAS  PubMed  Google Scholar 

  32. de Seze M, et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002;42(1):56–62.

    Article  PubMed  Google Scholar 

  33. Gallien P, et al. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76(12):1670–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Maria G, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003;62(2):259–64; discussion 264-5.

    Article  PubMed  Google Scholar 

  35. Chuang YC, et al. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology. 2005;66(4):775–9.

    Article  PubMed  Google Scholar 

  36. Chuang YC, et al. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. 2006;98(5):1033–7. discussion 1337

    Article  CAS  PubMed  Google Scholar 

  37. McVary KT, et al. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2014;192(1):150–6.

    Article  CAS  PubMed  Google Scholar 

  38. Marberger M, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013;63(3):496–503.

    Article  CAS  PubMed  Google Scholar 

  39. van de Merwe JP, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.

    Article  PubMed  Google Scholar 

  40. Smith CP, et al. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5. discussion 875

    Article  PubMed  Google Scholar 

  41. Kuo HC. Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int. 2005;75(2):170–4.

    Article  CAS  PubMed  Google Scholar 

  42. Giannantoni A, et al. Botulinum a toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol. 2006;49(4):704–9.

    Article  CAS  PubMed  Google Scholar 

  43. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104(5):657–61.

    Article  CAS  PubMed  Google Scholar 

  44. Pinto R, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010;58(3):360–5.

    Article  CAS  PubMed  Google Scholar 

  45. Kuo HC, et al. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2016;35(5):609–14.

    Article  CAS  PubMed  Google Scholar 

  46. Turner JA, et al. Primary care and urology patients with the male pelvic pain syndrome: symptoms and quality of life. J Urol. 2002;167(4):1768–73.

    Article  PubMed  Google Scholar 

  47. Zermann D, et al. Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol. 2000;38(4):393–9.

    Article  CAS  PubMed  Google Scholar 

  48. Gottsch HP, Yang CC, Berger RE. A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scand J Urol Nephrol. 2011;45(1):72–6.

    Article  CAS  PubMed  Google Scholar 

  49. Fam M, Gilhooly P. The use of botulinum neurotoxin type a in a patient with refractory urge incontinence to facilitate the intravesical treatment of bladder carcinoma. Rev Urol. 2014;16(4):194–7.

    PubMed  PubMed Central  Google Scholar 

  50. Lockwood G, Durkee C, Groth T. Intravesical Botulinum toxin for persistent autonomic dysreflexia in a pediatric patient. Case Rep Urol. 2016;2016:4569684.

    PubMed  PubMed Central  Google Scholar 

  51. Gupta M, et al. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010;183(2):598–602.

    Article  CAS  PubMed  Google Scholar 

  52. Reitz A, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45(4):510–5.

    Article  CAS  PubMed  Google Scholar 

  53. Patki PS, et al. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int. 2006;98(1):77–82.

    Article  CAS  PubMed  Google Scholar 

  54. Moore C, Rackley R, Goldman H. Urologic applications of botox. Curr Urol Rep. 2005;6(6):419–23.

    Article  PubMed  Google Scholar 

  55. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47(5):653–9.

    Article  CAS  PubMed  Google Scholar 

  56. Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30(7):1242–8.

    PubMed  Google Scholar 

  57. Samal V, Mecl J, Sram J. Submucosal administration of onabotulinumtoxinA in the treatment of neurogenic detrusor overactivity: pilot single-centre experience and comparison with standard injection into the detrusor. Urol Int. 2013;91(4):423–8.

    Article  CAS  PubMed  Google Scholar 

  58. Nitti VW. Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. Rev Urol. 2006;8(4):198–208.

    PubMed  PubMed Central  Google Scholar 

  59. Popat R, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005;174(3):984–9.

    Article  CAS  PubMed  Google Scholar 

  60. Sahai A, et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology. 2010;75(3):552–8.

    Article  PubMed  Google Scholar 

  61. Dowson C, et al. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2012;61(4):834–9.

    Article  CAS  PubMed  Google Scholar 

  62. Herschorn S, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229–35.

    Article  CAS  PubMed  Google Scholar 

  63. Rovner E, et al. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(8):1109–15.

    Article  CAS  PubMed  Google Scholar 

  64. Kalsi V, et al. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol. 2006;49(3):528–35.

    Article  PubMed  Google Scholar 

  65. Kessler TM, et al. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn. 2005;24(3):231–6.

    Article  CAS  PubMed  Google Scholar 

  66. Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol. 2010;58(6):919–26.

    Article  CAS  PubMed  Google Scholar 

  67. Oeconomou A, et al. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol. 2008;54(4):765–75.

    Article  CAS  PubMed  Google Scholar 

  68. BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. 2016. 1/2016. http://www.allergan.com/assets/pdf/botox_pi.pdf.

  69. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol. 2004;171(6 Pt 1):2128–37.

    Article  CAS  PubMed  Google Scholar 

  70. Sahai A, et al. Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn. 2005;24(1):2–12.

    Article  CAS  PubMed  Google Scholar 

  71. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol. 2003;44(2):165–74.

    Article  CAS  PubMed  Google Scholar 

  72. Visco AG, et al. Cost-effectiveness analysis of anticholinergics versus Botox for urgency urinary incontinence: results from the anticholinergic versus Botox comparison randomized trial. Female Pelvic Med Reconstr Surg. 2016;22(5):311–6.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Wu JM, et al. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol. 2009;181(5):2181–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Rutgers New Jersey Medical School, Newark, NJ, USA

    Saman Shafaat Talab M.D., Hossein Sadeghi-Nejad M.D., F.A.C.S & Patricia E. Gilhooly M.D., F.A.C.S

  2. VA New Jersey Health Care System, East Orange, NJ, USA

    Hossein Sadeghi-Nejad M.D., F.A.C.S & Patricia E. Gilhooly M.D., F.A.C.S

Authors
  1. Saman Shafaat Talab M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hossein Sadeghi-Nejad M.D., F.A.C.S
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patricia E. Gilhooly M.D., F.A.C.S
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saman Shafaat Talab M.D. .

Editor information

Editors and Affiliations

  1. Emeritus Professor of Neurology, Yale University, New Haven, Connecticut, USA

    Bahman Jabbari

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Talab, S.S., Sadeghi-Nejad, H., Gilhooly, P.E. (2018). Applications of Botulinum Toxin in the Urinary Tract. In: Jabbari, B. (eds) Botulinum Toxin Treatment in Clinical Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-56038-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56038-0_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56037-3

  • Online ISBN: 978-3-319-56038-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation